Pascoe Richard W
CIK 0001343266 Name as filed on the most recent filing
Filed as Pascoe Richard W (17)
30 transaction lines · from 17 filings · filed 2010-01-05 to 2023-03-13 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Zevra Therapeutics, Inc. 5 filings
- ISSUER Histogen Inc. 2 filings
- ISSUER Apricus Biosciences, Inc. 3 filings
- ISSUER Somaxon Pharmaceuticals, Inc. 7 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
30 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2023-03-09 |
Zevra Therapeutics, Inc. ZVRA |
P, Open-market purchase | 10,000 acquired | 4.20 | 41,978.00 | Form 4, filing 0001437749-23-006274 | |
| 2023-01-13 |
Kempharm, Inc KMPH |
P, Open-market purchase | 9,500 acquired | 5.44 | 51,679.05 | Form 4, filing 0001437749-23-001059 | |
| 2022-05-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 1,767 acquired | 4.92 | 8,693.64 | Form 4, filing 0001437749-22-012933 | |
| 2022-05-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 1,700 acquired | 4.93 | 8,381.00 | Form 4, filing 0001437749-22-012933 | |
| 2022-05-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 400 acquired | 4.91 | 1,964.00 | Form 4, filing 0001437749-22-012933 | |
| 2022-05-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 400 acquired | 4.91 | 1,963.96 | Form 4, filing 0001437749-22-012933 | |
| 2022-05-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 333 acquired | 4.94 | 1,645.02 | Form 4, filing 0001437749-22-012933 | |
| 2022-05-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 300 acquired | 4.90 | 1,469.97 | Form 4, filing 0001437749-22-012933 | |
| 2022-05-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 100 acquired | 4.90 | 490.00 | Form 4, filing 0001437749-22-012933 | |
| 2021-11-30 |
Kempharm, Inc KMPH |
P, Open-market purchase | 1,500 acquired | 7.88 | 11,822.10 | Form 4, filing 0001437749-21-027582 | |
| 2021-03-30 |
Histogen Inc. HSTO |
P, Open-market purchase | 20,000 acquired | 1.14 | 22,800.00 | Form 4, filing 0001209191-21-023623 | |
| 2020-12-03 |
Histogen Inc. HSTO |
P, Open-market purchase | 10,000 acquired | 1.24 | 12,394.00 | Form 4, filing 0001209191-20-061926 | |
| 2020-08-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 7,200 acquired | 0.63 | 4,564.80 | Form 4, filing 0001437749-20-018279 | |
| 2020-08-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 1,800 acquired | 0.64 | 1,152.00 | Form 4, filing 0001437749-20-018279 | |
| 2020-08-18 |
Kempharm, Inc KMPH |
P, Open-market purchase | 1,000 acquired | 0.64 | 635.00 | Form 4, filing 0001437749-20-018279 | |
| 2014-12-22 |
Apricus Biosciences, Inc. APRI |
P, Open-market purchase | 10,000 acquired | 1.02 | 10,217.00 | Form 4, filing 0001017491-14-000120 | |
| 2014-10-22 |
Apricus Biosciences, Inc. APRI |
P, Open-market purchase | 12,000 acquired | 1.51 | 18,120.00 | Form 4, filing 0001017491-14-000095 | |
| 2013-05-23 |
Apricus Biosciences, Inc. APRI |
P, Open-market purchase | 35,000 acquired | 2.85 | 99,750.00 | Form 4, filing 0001181431-13-030749 | |
| 2012-01-03 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 18,750 disposed | 0.48 | 8,943.75 | Form 4, filing 0001209191-12-000919 | |
| 2011-06-10 |
Somaxon Pharmaceuticals, Inc. SOMX |
P, Open-market purchase | 11,100 acquired | 2.25 | 24,942.81 | Form 4, filing 0001209191-11-034177 | |
| 2010-12-01 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 13,781 disposed | 2.68 | 36,977.18 | Form 4, filing 0001209191-10-058428 | |
| 2010-03-18 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 76,300 disposed | 5.62 | 429,111.20 | Form 4, filing 0001209191-10-018090 | |
| 2010-03-18 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 15,100 disposed | 6.42 | 96,928.41 | Form 4, filing 0001209191-10-018090 | |
| 2010-03-18 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 4,800 disposed | 7.53 | 36,156.00 | Form 4, filing 0001209191-10-018090 | |
| 2010-03-18 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 4,510 disposed | 6.50 | 29,311.39 | Form 4, filing 0001209191-10-018090 | |
| 2010-03-18 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 2,600 disposed | 8.74 | 22,719.06 | Form 4, filing 0001209191-10-018090 | |
| 2010-03-18 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 1,200 disposed | 9.58 | 11,490.96 | Form 4, filing 0001209191-10-018090 | |
| 2010-03-01 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 40,000 disposed | 4.01 | 160,524.00 | Form 4, filing 0001209191-10-014263 | |
| 2010-02-05 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 62,000 disposed | 3.03 | 187,599.60 | Form 4, filing 0001209191-10-007983 | |
| 2009-12-31 |
Somaxon Pharmaceuticals, Inc. SOMX |
S, Open-market sale | 8,000 disposed | 1.07 | 8,546.40 | Form 4, filing 0001209191-10-001303 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 19
- Open-market sale 11
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Pascoe Richard W, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001343266
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6